ReviewiScience2026
Perilipins: Current perspectives on the role in cardiovascular diseases.
Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The perilipin (PLIN) protein family serves as key structural and regulatory proteins on the surface of lipid droplets (LDs), which in turn ensures the storage and mobilization of fatty acids (FAs) in cardiac cells, thereby promoting FAs oxidation and playing a central role in the regulation of cardiomyocytes. Cardiovascular diseases (CVDs) are extremely fatal diseases in today's society, and the prevalence of CVDs increases with age. Its pathophysiology is complex, and the occurrence of CVDs is closely associated with abnormalities in lipid metabolism. Members of the PLIN protein family has been shown to be involved in the cellular function and metabolism-related signaling pathways of various diseases. We primarily review the roles of the PLIN protein family in CVDs and their metabolic mechanisms and propose that targeting PLIN directly or indirectly through pharmacological interventions may influence systemic lipid metabolism, offering a promising therapeutic avenue for improving cardiac function and alleviating metabolically disruptive lipotoxicity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.